OncoMed CMO Jakob Dupont resigns
Dr. Dupont expects to return to Genentech/Roche in a position of significant responsibility in oncology clinical development. Dr. Dupont is a medical Oncologist with extensive academic and pharmaceutical oncology drug development experience.
Dr. Dupont joined OncoMed from Genentech, a member of the Roche Group, where he was Global Medical Director for Avastin (bevacizumab). While at Genentech, Dr. Dupont held leadership positions at all stages of oncology drug development from Phase 1 through Phase IV.
Prior to this, Dr. Dupont held development leadership positions on the Avastin franchise for the Breast Cancer and the Ovarian Cancer indications. He also held leadership position in the Exploratory Clinical Development group overseeing the development activities of the oncology angiogenesis pipeline at Genentech.
In his academic work, Dr. Dupont helped to develop a number of key oncology drugs including: Zaltrap (ziv-aflibercept); ALIMTA (pemetrexed); XyotaxT (paclitaxel poliglumex); VELCADE (bortezomib); and several other new molecular oncologic entities.
Prior to his work with industry, Dr. Dupont held a faculty appointment at Memorial Sloan-Kettering Cancer Center where he oversaw a Phase 1 Solid Tumor and gynecologic oncology clinic and led an immunology and translational laboratory.
He received his M.D. from Weill Medical College of Cornell and completed his Internal Medicine training at the University of Michigan and the New York-Presbyterian Hospital. He went on to complete his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center.
Dr. Dupont has received numerous grants and awards and been an author on more than forty peer-review publications. He continues to care for gynecologic oncology patients and teach as an Adjunct Clinical Assistant Professor at Stanford University Medical Center.
Dr. Dupont's resignation will be effective on or about January 1, 2017 in order to facilitate a smooth transition.
Robert Stagg, Pharm.D., will lead clinical development and clinical operations at the company. He has served as OncoMed's Vice President, Clinical Research for over nine years.
Jill Henrich, OncoMed's Vice President, Regulatory Affairs for almost eight years, will continue to lead the company's regulatory and quality functions. ■
LATEST MOVES FROM California
- CBRE Group appoints Beth F. Cobert to board
- Cloudera appoints two to board
- Verifone appoints Rowan Trollope to board of directors
- Catasys appoints Christopher Shirley as CFO
- Silicon Valley Bank promotes Michael Descheneaux to president
More inside POST
Uber officially enters trucking industry Companies